Intergroup Emotions, Perceived Threats and Hostility against Foreigners: Comparing Brazil, Portugal, and Spain

This study analyzed whether hostility towards foreigners perceived as competitors in the labor market would be related to the perception of threat (symbolic and economic) and negative intergroup emotions. 270 people between 18 and 63 years participated. In Brazil (N = 89), mostly men (59%) and average age 32.5 years; In Portugal (N = 87), mostly men (56.3%) and average age 39.9 years; in Spain (N = 94), mostly women (53.2%) and average age of 32.8 years. The results (t-test, analysis of variance and multiple regressions) indicated that in Spain negative emotions are associated with less hostility towards immigrants; In Brazil, positive emotions are associated with hostile attitudes. In Portugal, the relationship between positive emotions and hostility is positive, but not signifi cant. The symbolic threat was the best predictor of hostility only in the Brazilian sample. Positive emotions predispose to a greater kindness towards foreigners in the three countries. The main conclusion of the study is that the economic crisis does not seem to be associated with the perception of competitiveness of foreigners in the local labor market and hostility towards this social group.O estudo analisou se a hostilidade para com estrangeiros percebidos como concorrentes no mercado de trabalho estaria relacionada com a percepção de ameaça (simbólica e econômica) e as emoções intergrupais negativas. Participaram 270 pessoas entre 18 e 63 anos, assim distribuídas: Brasil (N = 89), idade média de 32.5 anos, maioria de homens (59%); Portugal (N = 87), idade média de 39.9 anos, maioria de homens (56.3%); e Espanha (N=94), idade média de 32.8 anos, maioria de mulheres (53.2%). Os resultados do Teste-t, análise da variância e regressões múltiplas indicaram que enquanto na Espanha emoções negativas se associam a menos hostilidade para com imigrantes, no Brasil é a expressão de emoções positivas que se encontra associada a tais atitudes hostis. Em Portugal a relação entre emoções positivas e hostilidade é positiva, mas não signifi cativa. A ameaça simbólica foi o melhor preditor de hostilidade somente na amostra brasileira. Emoções positivas predizem maior amabilidade para com estrangeiros nas amostras dos três países. A principal conclusão do estudo é que a crise econômica não parece estar associada com a percepção de competitividade do estrangeiro no mercado de trabalho local e a hostilidade para com este grupo social.info:eu-repo/semantics/publishedVersio

Efficacy of naproxen with or without esomeprazole for pain and inflammation in patients after bilateral third molar extractions : a double blinded crossover study

Using a double-blinded randomized crossover design, this study aimed to evaluate acute postoperative pain management, swelling and trismus in 46 volunteers undergoing extractions of the two lower third molars, in similar positions, at two different appointments who consumed a tablet of either NE (naproxen 500 mg + esomepraz ole 20 mg) or only naproxen (500 mg) every 12 hours for 4 days. Parameters were analyzed: self-reported pain intensity using a visual analog scale (VAS) pre- and postoperative mouth opening; incidence, type and severity of adverse reactions; total quantity consumed of rescue medication; and pre- and postoperative swelling. Female volunteers reported significantly more postoperative pain at 1, 1.5, 2, 3 and 4hrs after surgery while also taking their first rescue medication at a time significantly earlier when consuming NE when compared to naproxen (3.7hrs and 6.7hrs). Conversely, no differences were found between each drug group in males. In conclusion, throughout the entire study, pain was mild after using either drug in both men and women with pain scores on average well below 40mm (VAS), although in women naproxen improved acute postoperative pain management when compared to NE

Morte encefálica e cuidados na manutenção do potencial doador de órgãos e tecidos para transplante

Este trabalho trata-se de estudo exploratório-descritivo com abordagem quantitativa e dados prospectivos que objetivou verificar o conhecimento dos profissionais de enfermagem sobre a Morte Encefálica (ME) e a manutenção do Potencial Doador (PD). A população constou de 55 profissionais de enfermagem. Destes, a maioria eram técnicos em enfermagem (74,5%); 78,2% informaram já ter trabalhado com PDs e 50,9% afirmaram estar preparados para cuidar desses pacientes. Das condições indispensáveis para a abertura do protocolo de ME, 49,1% afirmaram erroneamente a temperatura superior a 36ºC. No manejo dos distúrbios hidroeletrolíticos, 50,9% optaram incorretamente sobre a reposição de sódio, potássio e magnésio. Nos cuidados com córneas, 58,2% optaram erradamente sobre a proteção com gaze. E 52,7% afirmaram corretamente que o PD pode ser reanimado. O conhecimento sobre o diagnóstico de ME e manutenção ao PD era insuficiente entre os pesquisados, necessitando de educação sobre o tema a fim de aumentar a oferta de órgãos/tecidos para transplantes. Descritores: Enfermagem; Morte Encefálica; Transplante; Unidade de Terapia Intensiva

A European spectrum of pharmacogenomic biomarkers: Implications for clinical pharmacogenomics

Pharmacogenomics aims to correlate inter-individual differences of drug efficacy and/or toxicity with the underlying genetic composition, particularly in genes encoding for protein factors and enzymes involved in drug metabolism and transport. In several European populations, particularly in countries with lower income, information related to the prevalence of pharmacogenomic biomarkers is incomplete or lacking. Here, we have implemented the microattribution approach to assess the pharmacogenomic biomarkers allelic spectrum in 18 European populations, mostly from developing European countries, by analyzing 1,931 pharmacogenomics biomarkers in 231 genes. Our data show significant interpopulation pharmacogenomic biomarker allele frequency differences, particularly in 7 clinically actionable pharmacogenomic biomarkers in 7 European populations, affecting drug efficacy and/or toxicity of 51 medication treatment modalities. These data also reflect on the differences observed in the prevalence of high-risk genotypes in these populations, as far as common markers in the CYP2C9, CYP2C19, CYP3A5, VKORC1, SLCO1B1 and TPMT pharmacogenes are concerned. Also, our data demonstrate notable differences in predicted genotype-based warfarin dosing among these populations. Our findings can be exploited not only to develop guidelines for medical prioritization, but most importantly to facilitate integration of pharmacogenomics and to support pre-emptive pharmacogenomic testing. This may subsequently contribute towards significant cost-savings in the overall healthcare expenditure in the participating countries, where pharmacogenomics implementation proves to be cost-effective

Instrument for assessing the quality of mobile emergency pre-hospital care: content validation

OBJECTIVES To validate an instrument to assess quality of mobile emergency pre-hospital care. METHOD A methodological study where 20 professionals gave their opinions on the items of the proposed instrument. The analysis was performed using Kappa test (K) and Content Validity Index (CVI), considering K> 0.80 and CVI ≥ 0.80. RESULTS Three items were excluded from the instrument: Professional Compensation; Job Satisfaction and Services Performed. Items that obtained adequate K and CVI indexes and remained in the instrument were: ambulance conservation status; physical structure; comfort in the ambulance; availability of material resources; user/staff safety; continuous learning; safety demonstrated by the team; access; welcoming; humanization; response time; costumer privacy; guidelines on care; relationship between professionals and costumers; opportunity for costumers to make complaints and multiprofessional conjunction/actuation. CONCLUSION The instrument to assess quality of care has been validated and may contribute to the evaluation of pre-hospital care in mobile emergency services

Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry

Low-frequency variants play an important role in breast cancer (BC) susceptibility. Gene-based methods can increase power by combining multiple variants in the same gene and help identify target genes. We evaluated the potential of gene-based aggregation in the Breast Cancer Association Consortium cohorts including 83,471 cases and 59,199 controls. Low-frequency variants were aggregated for individual genes' coding and regulatory regions. Association results in European ancestry samples were compared to single-marker association results in the same cohort. Gene-based associations were also combined in meta-analysis across individuals with European, Asian, African, and Latin American and Hispanic ancestry. In European ancestry samples, 14 genes were significantly associated (q < 0.05) with BC. Of those, two genes, FMNL3 (P = 6.11 × 10 ) and AC058822.1 (P = 1.47 × 10 ), represent new associations. High FMNL3 expression has previously been linked to poor prognosis in several other cancers. Meta-analysis of samples with diverse ancestry discovered further associations including established candidate genes ESR1 and CBLB. Furthermore, literature review and database query found further support for a biologically plausible link with cancer for genes CBLB, FMNL3, FGFR2, LSP1, MAP3K1, and SRGAP2C. Using extended gene-based aggregation tests including coding and regulatory variation, we report identification of plausible target genes for previously identified single-marker associations with BC as well as the discovery of novel genes implicated in BC development. Including multi ancestral cohorts in this study enabled the identification of otherwise missed disease associations as ESR1 (P = 1.31 × 10 ), demonstrating the importance of diversifying study cohorts. [Abstract copyright: © 2023. The Author(s).

Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk

In breast cancer, high levels of homeobox protein Hox-B13 (HOXB13) have been associated with disease progression of ER-positive breast cancer patients and resistance to tamoxifen treatment. Since HOXB13 p.G84E is a prostate cancer risk allele, we evaluated the association between HOXB13 germline mutations and breast cancer risk in a previous study consisting of 3,270 familial non-BRCA1/2 breast cancer cases and 2,327 controls from the Netherlands. Although both recurrent HOXB13 mutations p.G84E and p.R217C were not associated with breast cancer risk, the risk estimation for p.R217C was not very precise. To provide more conclusive evidence regarding the role of HOXB13 in breast cancer susceptibility, we here evaluated the association between HOXB13 mutations and increased breast cancer risk within 81 studies of the international Breast Cancer Association Consortium containing 68,521 invasive breast cancer patients and 54,865 controls. Both HOXB13 p.G84E and p.R217C did not associate with the development of breast cancer in European women, neither in the overall analysis (OR = 1.035, 95% CI = 0.859-1.246, P = 0.718 and OR = 0.798, 95% CI = 0.482-1.322, P = 0.381 respectively), nor in specific high-risk subgroups or breast cancer subtypes. Thus, although involved in breast cancer progression, HOXB13 is not a material breast cancer susceptibility gene.Peer reviewe

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10-8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers